$INO 
Inovio CEO J. Joseph Kim, Ph.D., isn’t rattled. Earlier this week, his company released animal data showing its DNA vaccine, INO-4800, generated neutralizing antibodies against SARS-CoV-2, the virus that causes the infection, along with a promise that preliminary data from a phase 1 human trial will be out in June.

“Our 40 volunteers should be getting their second dose by early next week, after the Memorial Day holiday,” he told FierceBiotech. Starting in mid-June, he added, “our team will be working overtime to run all of the assays as rapidly as possible.”
Inovio hopes to start a phase 2/3 efficacy trial in July, Kim added, which would generate long-term efficacy data on INO-4800 in about a year. But if the company has the opportunity to seek approval earlier than that, it will.

“If an emergency approval path is available, based on safety and immune responses to date, we will file for that approval,” Kim said.
<ticker> <company> ceo j . joseph kim , ph . d . , is not rattled . earlier this week , his company released animal data showing its dna vaccine , ino - <number> , generated neutralizing antibodies against sars - cov - <number> , the virus that causes the infection , along with a promise that preliminary data from a phase <number> human trial will be out in june . our <number> volunteers should be getting their second dose by early next week , after the memorial day holiday , he told fiercebiotech . starting in mid - june , he added , our team will be working overtime to run all of the assays as rapidly as possible . <company> hopes to start a phase <number> / <number> efficacy trial in july , kim added , which would generate long - term efficacy data on ino - <number> in about a year . but if the company has the opportunity to seek approval earlier than that , it will . if an emergency approval path is available , based on safety and immune responses to date , we will file for that approval , kim said .